(4-Nitrosophenyl) acetate | 83154-99-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: (4-Nitrosophenyl) acetate
• CAS: 83154-99-8
• 化学式: C₈H₇NO₃
• 分子量: 165.148
• InChiKey: YPTSUUUOSBNVDD-UHFFFAOYSA-N

物化性质

• 沸点：
  267.5±23.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  乙酸酐 、 potassium salt of p-nitrosophenol 在 18-冠醚-6 作用下， 以 乙腈 为溶剂， 生成 potassium acetate 、 (4-Nitrosophenyl) acetate
  参考文献：
  名称：

  Kinetics and some equilibriums of transacylation between oxy anions in aprotic solvents

  摘要：

  DOI：

  10.1021/jo00133a001

文献信息

• High Quantum Yield Acridinium Compounds and Their Uses in Improving Assay Sensitivity
  申请人：Natrajan Anand

  公开号：US20080014660A1

  公开（公告）日：2008-01-17

  The present invention relates to hydrophilic, high quantum yield acridinium compounds. It has been discovered that the placement of electron-donating groups in the acridinium ring system increases the amount of light that is emitted by the corresponding acridinium compound when its chemiluminescence is triggered by alkaline peroxide. More specifically, it has been found that the placement of one or two hydrophilic, alkoxy groups at the C-2 and/or C-7 position of the acridinium ring system of acridinium compounds increases their quantum yield and enhances the aqueous solubility of these compounds. The present hydrophilic, high quantum yield, acridinium compounds are useful chemiluminescent labels for improving the sensitivity of immunoassays.

  本发明涉及亲水性高量子产率的吖啶类化合物。已经发现，在吖啶环系中引入电子供体基团可以增加相应吖啶化合物在碱性过氧化物引发的化学发光时所发射的光量。更具体地，发现在吖啶环系的C-2和/或C-7位置引入一个或两个亲水性的烷氧基团可以增加吖啶类化合物的量子产率并提高这些化合物的水溶性。本发明的亲水性高量子产率的吖啶类化合物是用于提高免疫分析灵敏度的有用化学发光标记。
• Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
  申请人：Doronina Svetlana O.

  公开号：US20090111756A1

  公开（公告）日：2009-04-30

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

  具有C-末端苯丙氨酸羧基酸等效物的MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物已经制备，并通过各种连接剂（包括maleimidocaproyl-val-cit-PAB）连接到配体上。 结果得到的配体药物结合物在体外和体内均具有活性。
• MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS
  申请人：Doronina Svetlana O.

  公开号：US20120034247A1

  公开（公告）日：2012-02-09

  Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

  Auristatin肽包括MeVal-Val-Dil-Dap-Norephedrine（MMAE）和MeVal-Val-Dil-Dap-Phe（MMAF），通过各种连接剂，包括maleimidocaproyl-val-cit-PAB，制备并附着到配体上。得到的配体药物结合物在体外和体内均具有活性。
• Multi-Day Delivery Of Biologically Active Substances
  申请人：Kydonieus Agis

  公开号：US20110046599A1

  公开（公告）日：2011-02-24

  Compositions and methods for modifying biologically active substances to achieve multi-day delivery of such substances, particularly through oral or parenteral administration, are disclosed. The compositions include the biologically active substance conjugated to a carrier having a suitably long half life, typically more than one day, wherein the conjugate optionally contains a spacer linking the carrier to the biologically active substance. Pharmaceutical formulations of the conjugates are also disclosed, as are methods of extending delivery of a single dose of a biologically active substance for more than one day.

  本发明揭示了用于修改生物活性物质以实现多日输送的组合物和方法，特别是通过口服或静脉注射途径。这些组合物包括与具有适当长寿命（通常超过一天）的载体结合的生物活性物质，其中该共轭体可选地包含将载体与生物活性物质连接的间隔物。本发明还揭示了该共轭体的制药配方，以及延长单剂量生物活性物质输送超过一天的方法。
• Compositions and methods for detection of lysosomal storage disease
  申请人：GENZYME CORPORATION

  公开号：EP2535050A2

  公开（公告）日：2012-12-19

  The present invention provides compositions for performing assays of enzyme activity associated with lysosomal storage diseases. The invention further provides methods for determining enzyme activity, and methods for the screening for lysosomal storage disease in an individual.

  本发明提供了用于检测与溶酶体贮积疾病相关的酶活性的组合物。本发明进一步提供了确定酶活性的方法，以及筛查个体溶酶体贮积症的方法。